The debut of troglitazone, a potent insulin-sensitizing agent, marked a significant chapter in the treatment of type 2 diabetes. However, its discontinuation from the market due to substantial hepatotoxicity spurred https://arunfyhq395086.blog5.net/91718990/troglitazone-and-related-glitazones-a-relative-overview